跳至主要内容
临床试验/NCT04532697
NCT04532697已完成不适用

Efficacy of Uncaria Rhynchophylla (Gou-Teng) for Patients With Mild Cognitive Impairment: A Pilot Randomized Controlled Trial Using White Matter Hyperintensities Estimated by ARIA as Outcome

Chinese University of Hong Kong1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2020年11月24日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
56
试验地点
1
主要终点
HK-MoCA

研究概览

简要总结

Mild cognitive impairment (MCI) is a pre-dementia condition commonly occurs in elderly people. As Hong Kong has become an aged society, the prevalence of dementia and MCI in Hong Kong has increased substantially in recent decades. To date, no effective pharmacological therapies are available for MCI, and there exists a need for exploring complementary treatment for this age-related condition. Preclinical studies have identified Uncaria rhynchophylla (Gouteng in Chinese) to have promising neuroprotective effect in Alzheimer's disease experimental models.

Objective: To assess the effectiveness and the safety of oral administration of Uncaria rhynchophylla for MCI in older people in Hong Kong.

Study design: This is a double-blinded, randomized, placebo controlled pilot study. 56 patients with MCI will be randomized into two groups i.e. Uncaria rhynchophylla and placebo groups. All subjects will receive treatment twice a day for a consecutive 16 weeks.

详细描述

It is hypothesized that U. rhynchophylla may have good therapeutic efficacy for the treatment of MCI. However, up to now, there exists no clinical data to support the use of U.rhynchophylla for MCI. To evaluate the efficacy of U. rhynchophylla for MCI, the investigator will use a fully automatic retinal image analysis (ARIA) method to estimate the WMH and use this as one of the outcome measures.

The aim of this pilot study is to evaluate the effectiveness and safety of a Chinese herbal preparation U. rhynchophylla for subjects with mild cognitive impairment. It is hypothesized that treatment with U. rhynchophylla is able to significantly improve the cognitive function of subjects with MCI and reduce the white matter hyperintensities (WMH) in the brain of these subjects.

All eligible subjects will be randomly assigned to receive a treatment of either Uncaria rhynchophylla or placebo for 16 weeks followed by 8 weeks observation. All subjects, both of the intervention and control group, will receive standard routine care from the conventional healthcare system.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

All the participants, outcome assessors and the investigator are all masked, only the staff preparing the study product know the treatment arm.

入排标准

年龄范围
65 Years 至 —(Older Adult)
性别
All
接受健康志愿者

入选标准

  • Both male and female individuals aged 65 years or over at their last birthday
  • Montreal Cognitive Assessment (Hong Kong version) (HK-MoCA) age/education matched percentile (score), with the cut off score of ≤16th percentile
  • Understand the questionnaires used in the study
  • Agreement to give informed consent

排除标准

  • Known dementia including Alzheimer's disease
  • Current drug use for the treatment of MCI or dementia
  • Patient Health Questionnaire-9 (PHQ-9) score 15 or more
  • Known psychiatric diseases such as depressive episode, bipolar disorder, obsessive-compulsive disorder and schizophrenia;
  • Known history of seizures;
  • Known history of stroke associated with permanent disability;
  • Known history of liver and renal impairment;
  • Known history of allergy to Chinese herbal medicine;
  • Concomitant use of warfarin or any anti-coagulants
  • Current history of hazardous or harmful alcohol consumption;
  • Current medical history that prevented participation in the study tasks such as sensory impairment and advanced cancer;
  • Current use of any kind of herbal medicine for the prevention and treatment of dementia.

研究组 & 干预措施

Chinese Medicine

Active Comparator

Uncaria Rhynchophylla (Gou-Teng)

干预措施: Uncaria Rhynchophylla (Gou-Teng) (Other)

Placebo treatment

Placebo Comparator

Placebo

干预措施: Placebo (Other)

结局指标

主要结局

HK-MoCA

时间窗: 16 weeks

The Montreal Cognitive Assessment (MoCA) was designed as a rapid screening instrument for mild cognitive dysfunction. Scoring of HK MoCA ranges from 0 to 30 points. 3 cutoff percentile will be used: 2nd, 7th, and 16th percentile. The cut-off percentile at 16th above is considered normal and it shows worse with the decreasing percentile.

次要结局

  • Automatic Retinal Image Analysis (ARIA)(24 weeks)
  • HK-MoCA(24 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Prof. Lin Zhixiu

Professor

Chinese University of Hong Kong

研究点 (1)

Loading locations...

相似试验